BioNotebook: Calithera, Charleston, Cara, StemCells
This article was originally published in Scrip
Executive Summary
Calithera raises $35m in Series D round; Charleston halts Phase III on strong data; Cara reports positive Phase II results; and StemCells acquires key patents.